908 Devices (MASS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 May, 2026Executive summary
Q1 2026 revenue reached $13.4 million, up 14% year-over-year, driven by growth in both Mass Spec and FTIR segments and strong U.S. state and local sales.
Achieved significant strategic transformation in 2025, including positive adjusted EBITDA in Q4 and an installed base exceeding 3,900 devices by March 2026.
Acquisition of NIRLAB AG announced/completed in May 2026, expanding drug detection capabilities, recurring revenue streams, and international reach.
Integration of RedWave FTIR portfolio and successful product launches, such as VipIR, contributed to sustained growth and innovation.
Law enforcement and corrections markets remain key, with notable impact from initiatives like Virginia's Operation Free and regulatory changes.
Financial highlights
Q1 2026 product revenue was $10.7 million, up 26% year-over-year, with recurring revenue at $4.0 million (30% of total), and service/contract revenue at $2.6 million.
Gross profit was $6.9 million (GAAP, 51–52% margin), with adjusted gross margin at 57%; adjusted EBITDA loss narrowed to $2.5 million from $4.6 million year-over-year.
Net loss from continuing operations was $12.0 million, impacted by non-cash contingent consideration charges.
Cash, cash equivalents, and marketable securities totaled $111.7 million as of March 31, 2026, with no debt.
Operating expenses increased to $19.8 million, mainly due to contingent consideration related to RedWave.
Outlook and guidance
2026 revenue guidance raised to $67–$70 million, representing 19–25% growth over 2025, reflecting NIRLAB integration.
Handheld product and service revenue expected to grow 18–21% year-over-year.
Adjusted gross margins projected in the mid to high 50% range for 2026, with a goal of 100 bps improvement.
Adjusted EBITDA loss expected to be in the mid-single-digit millions, with positive adjusted EBITDA targeted for 2027.
Recurring revenue expected to expand, with software, service, and support opportunities exceeding $10 million per year.
Latest events from 908 Devices
- Transformation and innovation drive strong growth outlook, with profitability in near sight.MASS
Sidoti March Small-Cap Virtual Conference29 Apr 2026 - Virtual annual meeting set for June 11, 2026, with key votes on directors and compensation.MASS
Proxy filing29 Apr 2026 - Annual meeting to vote on directors, auditor, executive pay, and governance policies.MASS
Proxy filing29 Apr 2026 - Strong growth, innovation, and global expansion set the stage for profitability by 2027.MASS
Leerink Global Healthcare Conference 20269 Mar 2026 - Up to $100 million in securities to fund growth in handheld chemical analysis markets.MASS
Registration Filing9 Mar 2026 - Handheld detection tools, new products, and software drive growth and recurring revenue in 2026.MASS
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 18% to $56.2M, margins hit 57%, and Q4 Adjusted EBITDA turned positive.MASS
Q4 20253 Mar 2026 - Q2 revenue up 16% to $14M; 2024 outlook reaffirmed at $63–$65M, with strong handheld growth.MASS
Q2 20242 Feb 2026 - Handheld growth, RedWave integration, and innovation set the stage for future acceleration.MASS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026